-
Plant Extract Varieties with Great Market Potential
PharmaSources.com
March 12, 2021
The following plant extract varieties is considered to have great potential after summarizing various buying information and the sales of plant extracts in the U.S. market last year.
-
Junshi’s Anti-PD-1 Drug Achieved Sales of RMB1.3 Billion in 2020
PharmaSources/Caicai
March 12, 2021
Junshi Biosciences has recently announced its 2020 annual performance preview, according to which, it achieved operating income of RMB1.595 billion, up 105.77% year on year, mainly thanks to the sales revenue growth of its anti-PD-1 drug.
-
Neutralizing Antibodies, the “Specific Drugs” against SARS-CoV-2
PharmaSources/Yefenghong
March 04, 2021
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has developed into a global pandemic and become a serious public health and socioeconomic burden, and thus there is an urgent need for effective means of control.
-
Qilu Pharmaceutical Achieved Staggering Sales of Bevacizumab of RMB1.8 Billion in 2020
PharmaSources/Caicai
March 04, 2021
According to industry news, Qilu Pharmaceutical achieved sales of bevacizumab (trade name: Ankeda) of about RMB1.8 billion in 2020.
-
Analysis of the Export Market of Gelatin and Its Derivatives
PharmaSources/Chen Shipeng
February 19, 2021
Gelatin is a product made from animal bones, skins, muscles, tendons and scales after moderate hydrolysis (acid process, alkaline process, acid/alkaline process or enzymic method) and purification.
-
Enzymatic Synthesis of NMN: Greener and More Efficient
PharmaSources/Yuntian
February 19, 2021
NMN, i.e., nicotinamide mononucleotide (Fig. 1), is a reaction product of nicotinamide phosphoribosyltransferase (NAMPT).
-
A Review of Chinese-produced Class 1 New Drugs from 2018 to 2020
PharmaSources/Caicai
January 28, 2021
From 2018 to 2020, the marketing of Chinese-produced Class 1 new drugs entered the harvest period, with a total of 32 marketed (Chinese-produced Class 1 new drugs here refer to drugs registered under the classification of chemical drugs 1 and therapeutic.
-
NMN: A Star Drug on the Way toward a “Miracle Drug”
PharmaSources/Yuntian
January 28, 2021
As a new star API, NMN, i.e., nicotinamide mononucleotide, is a reaction product of nicotinamide phosphoribosyltransferase (NAMPT).
-
With So Many Different Adverse Reactions Following Vaccination, How to View COVID-19 Vaccination?
PharmaSources/Shanghai Xiaoyaoshi
January 27, 2021
Many people are concerned about the safety of the COVID-19 vaccines that have been developed so quickly worldwide.
-
How to Evaluate the Safety of COVID-19 Vaccines, Such as Adverse Reactions, Preclinically?
PharmaSources/Shanghai Xiaoyaoshi
January 21, 2021
Vaccines have effectively controlled many infectious diseases, however, the adverse reactions following vaccination cannot be always avoided.